Tildren Injection

Tildren® (Tiludronate disodium) is a bisphosphonate drug specifically developed for horses to manage bone resorption disorders such as navicular disease and osteolytic conditions.
It regulates bone metabolism by inhibiting osteoclastic activity, thereby reducing bone pain and improving mobility in affected animals.

Active Constituent (per mL)

• Tiludronate disodium – 5 mg

Pharmacological Action

Tildren acts by inhibiting bone resorption, reducing excessive bone turnover, and normalizing bone remodeling.
Through its action on osteoclasts, it prevents structural deterioration and helps alleviate lameness and chronic pain associated with navicular and degenerative joint diseases.

Indications

✅ Treatment of navicular syndrome in horses
✅ Management of osteolytic bone lesions
✅ Improvement of lameness and movement performance
✅ Supportive therapy in chronic bone pain or inflammation

Target Species

🐎 Horses only

Dosage & Administration

Route: Intravenous infusion (IV slow drip)

Treatment is typically given as a single infusion or repeated every 4–6 months depending on the severity and veterinary assessment.

Precautions

⚠️ Must be administered by a licensed veterinarian.
⚠️ Do not inject undiluted product directly.
⚠️ Avoid use in animals with renal impairment or dehydration.
⚠️ Ensure adequate hydration before and after infusion.
⚠️ Observe horse during and after infusion for signs of colic or restlessness.

Storage

• Store below 25°C

• Protect from light

• Do not freeze

Key Benefits

✔ Reduces lameness and chronic bone pain
✔ Improves bone structure and function
✔ Restores mobility and performance
✔ Long-lasting therapeutic effect
✔ Clinically proven in navicular syndrome management

Please refer to the product label or consult with your veterinarian for specific dosing recommendations.

Tiludronic acid 50 mg/vial (as disodium tiludronate 56.91 mg/vial) Powder and solvent for intravenous injection. Solvent is water for injection